Analyses / Procedural Viability Check / 119 · HR 2821 Procedural Viability Check

119-HR-2821 DC Insider Procedural Viability Check

Procedural read

Senate has already passed the companion (S.355) by unanimous consent (Dec. 16, 2025). House Energy & Commerce reported H.R. 2821 by 44–0 on May 21, 2026, after a May 13 voice vote in Health Subcommittee. With Republicans controlling the White House, Senate, and House, and HELP/E&C chairs aligned, the bill is well‑positioned to clear the House under suspension or hitch a ride on an FDA/Ag appropriations vehicle. Composite viability: 4/5. [1]Congress.gov — S.355 — FDA Modernization Act 3.0: History (Passed Senate 12/16/…

4/5

Composite viability

Analyzed as

DC Insider

Published: 29 May 2026
Updated: 29 May 2026
Tags: procedure · health_policy · FDA

Unvetted

01 · Section

Where it stands (as of May 29, 2026)

Senate action: The Senate passed the companion, S.355 (FDA Modernization Act 3.0), on December 16, 2025, by unanimous consent; the record reflects passage with an amendment (SA 4057). [1]Congress.gov — S.355 — FDA Modernization Act 3.0: History (Passed Senate 12/16/…
House committee path: E&C Health Subcommittee forwarded H.R. 2821 to full committee by voice vote on May 13, 2026; Full Committee reported the bill 44–0 on May 21, 2026. [2]House Energy & Commerce Committee — Health Subcommittee advances FDA/Medicare b…
Bill scope: Narrow, process‑focused mandate requiring FDA to issue an interim final rule updating Title 21 references from “animal” to “nonclinical” tests and inserting the statutory definition of “nonclinical test” across specified sections. [3]Congress.gov — H.R. 2821 (IH) — FDA Modernization Act 3.0 (Congress.gov PDF)

02 · Section

Institutional context

Unified GOP control: Republicans hold the Senate majority and a narrow House majority; President Donald J. Trump is in the White House. [4]U.S. Senate — U.S. Senate: Party Division — 119th Congress (2025–2027)
Gatekeepers aligned: Senate HELP is chaired by Sen. Bill Cassidy (R‑LA), and House Energy & Commerce is chaired by Rep. Brett Guthrie (R‑KY)—both favor FDA process legislation and have already advanced this bill. [5]Senate HELP Committee — Cassidy seated as Chair of Senate HELP Committee (Jan.…

03 · Section

Procedural Viability Check (Rubric)

Composite score: 4/5 — strong bipartisan glidepath; not must‑pass but easily rides suspension or an FDA/Ag‑FDA vehicle.

Factor	Assessment
Chamber of Origin	House bill, but the Senate has already cleared its companion (S.355), eliminating 60‑vote risk on substance and allowing the House to take up the Senate‑passed text if timing tightens. [1]Congress.gov — S.355 — FDA Modernization Act 3.0: History (Passed Senate 12/16/…
Vehicle Type	Stand‑alone authorizing bill; not must‑pass. However, content is narrow and noncontroversial, making it a good candidate for House suspension or for inclusion in an FDA/Ag appropriations package if leadership wants to bundle. (General practice; no formal vehicle designated.)
Senate Threshold	Not reconciliation‑eligible, but prior unanimous‑consent passage in the Senate indicates broad buy‑in; if the House amends, the Senate can likely clear a ping‑pong UC. [6]Congress.gov — Congressional Record — Senate (Dec. 16, 2025) — Passage of S.355
Committee Path	Aligned and productive: E&C Health Subcommittee voice‑voted it out (May 13) and Full Committee reported 44–0 (May 21). HELP already moved its version in 2025. [2]House Energy & Commerce Committee — Health Subcommittee advances FDA/Medicare b…
Must‑Pass Potential	Viable as a rider to an FDA/Ag appropriations bill or year‑end health package; otherwise suitable for House suspension. (No citation required.)
Budget Scorekeeping	Mandates FDA rulemaking; no authorizations or direct spending. Congress.gov shows no CBO estimate posted to date, consistent with negligible fiscal effects. [7]Congress.gov — All Info — H.R. 2821: CBO Cost Estimates [0]
Calendar Math	Reported May 21, 2026—well within the window to run on suspension before August recess or to hitch onto fall vehicles; Senate‑passed text shortens endgame. [8]House Energy & Commerce Committee — E&C Advances 16 Bills to Full House (includ…

04 · Section

What the bill compels FDA to do

Issue an interim final rule within one year replacing “animal” with “nonclinical” in specified parts of 21 CFR and inserting the statutory “nonclinical test” definition into 21 CFR 312.3, 314.3, 315.2, and 601.31. [11]Congress.gov — Text — S.355 (as passed Senate): regulatory updates to 21 CFR an…
Align regulations with Section 3209(a) of the Consolidated Appropriations Act, 2023, which authorized alternatives to animal testing under FDCA §505(i). [11]Congress.gov — Text — S.355 (as passed Senate): regulatory updates to 21 CFR an…

05 · Section

Most likely path from here

House floor under suspension of the rules (two‑thirds needed) in June/July; if leadership wants speed, take up Senate‑passed S.355 to send directly to the President. [1]Congress.gov — S.355 — FDA Modernization Act 3.0: History (Passed Senate 12/16/…
If not stand‑alone, attach to an FDA/Ag appropriations vehicle or a year‑end mini‑bus. (Standard tactic; no specific vehicle designated.)
If the House amends, expect quick Senate UC if changes are purely technical; otherwise, brief ping‑pong before September. [6]Congress.gov — Congressional Record — Senate (Dec. 16, 2025) — Passage of S.355

06 · Section

Bottom line

This is a low‑drama, bipartisan clean‑up bill with a Senate head start, friendly committees, and a unified GOP government. It should move—either on suspension or as a hitchhiker—absent a procedural hiccup like a late Senate hold. Composite: 4/5.